BIO.B vs. KEYS, FTV, VLTO, TER, RVTY, AVTR, NVMI, VNT, ST, and MIR
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Keysight Technologies (KEYS), Fortive (FTV), Veralto (VLTO), Teradyne (TER), Revvity (RVTY), Avantor (AVTR), Nova (NVMI), Vontier (VNT), Sensata Technologies (ST), and Mirion Technologies (MIR). These companies are all part of the "measuring and control equipment" industry.
Bio-Rad Laboratories vs.
Bio-Rad Laboratories (NYSE:BIO.B) and Keysight Technologies (NYSE:KEYS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.
Bio-Rad Laboratories has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Keysight Technologies has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
In the previous week, Keysight Technologies had 34 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 34 mentions for Keysight Technologies and 0 mentions for Bio-Rad Laboratories. Keysight Technologies' average media sentiment score of 1.05 beat Bio-Rad Laboratories' score of 0.00 indicating that Keysight Technologies is being referred to more favorably in the news media.
Keysight Technologies received 356 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 66.25% of users gave Keysight Technologies an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.
0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 84.6% of Keysight Technologies shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 0.6% of Keysight Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Keysight Technologies has a consensus price target of $184.44, suggesting a potential upside of 16.51%. Given Keysight Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Keysight Technologies is more favorable than Bio-Rad Laboratories.
Keysight Technologies has a net margin of 12.32% compared to Bio-Rad Laboratories' net margin of -71.86%. Keysight Technologies' return on equity of 19.22% beat Bio-Rad Laboratories' return on equity.
Keysight Technologies has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Keysight Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Keysight Technologies beats Bio-Rad Laboratories on 17 of the 18 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools
This page (NYSE:BIO.B) was last updated on 3/26/2025 by MarketBeat.com Staff
